| NKTR Stock | | | USD 1.10 0.14 14.58% |
SVP
Ms. Jillian B. Thomsen is Senior Vice President Finance, Chief Accounting Officer of the Company. From March 2006 through March 2008, Ms. Thomsen served as our Vice President Finance and Corporationrationrate Controller and from April 2008 through January 2010 she served as our Vice President Finance and Chief Accounting Officer. Before joining Nektar, Ms. Thomsen was Vice President Finance and Deputy Corporationrationrate Controller of Calpine Corporation from September 2002 to February 2006. Ms. Thomsen is a certified public accountant and previously was a senior manager at Arthur Andersen LLP, where she worked from 1990 to 2002, and specialized in audits of multinational consumer products, life sciences, manufacturing and energy companies since 2010.
| Age | 58 |
| Tenure | 15 years |
| Address | 455 Mission Bay Boulevard South, San Francisco, CA, United States, 94158 |
| Phone | 415 482 5300 |
| Web | https://www.nektar.com |
Thomsen holds a Masters of Accountancy from the University of Denver and a B.A. in Business Economics from Colorado College.
Nektar Therapeutics Management Efficiency
The company has return on total asset
(ROA) of
(0.2264) % which means that it has lost $0.2264 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
(1.6163) %, meaning that it created substantial loss on money invested by shareholders. Nektar Therapeutics' management efficiency ratios could be used to measure how well Nektar Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 01/04/2025,
Return On Tangible Assets is likely to grow to -0.76. In addition to that,
Return On Capital Employed is likely to grow to -0.34. At this time, Nektar Therapeutics'
Total Assets are relatively stable compared to the past year. As of 01/04/2025,
Non Currrent Assets Other is likely to grow to about 8.3
M, while
Other Assets are likely to drop slightly above 2.5
M.
Nektar Therapeutics currently holds 117.78
M in liabilities with Debt to Equity
(D/E) ratio of 0.33, which is about average as compared to similar companies. Nektar Therapeutics has a current ratio of 7.0, suggesting that it is
liquid enough and is able to pay its financial obligations when due. Note, when we think about Nektar Therapeutics' use of debt, we should always consider it together with its cash and equity.
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California. Nektar Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 740 people. Nektar Therapeutics (NKTR) is traded on NASDAQ Exchange in USA. It is located in 455 Mission Bay Boulevard South, San Francisco, CA, United States, 94158 and employs 137 people. Nektar Therapeutics is listed under Pharmaceuticals category by Fama And French industry classification.
Management Performance
Nektar Therapeutics Leadership Team
Elected by the shareholders, the Nektar Therapeutics' board of directors comprises two types of representatives: Nektar Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nektar. The board's role is to monitor Nektar Therapeutics' management team and ensure that shareholders' interests are well served. Nektar Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nektar Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jonathan Zalevsky, Senior Vice President - Research , Chief Scientific Officer | |
| Vivian Wu, Director Affairs | |
| Jennifer Ruddock, Vice President - Investor Relations and Corporate Affairs | |
| Mark Wilson, Chief Sec | |
| Sandra Gardiner, Interim Officer | |
| Kevin Brodbeck, VP Operations | |
| Mark JD, Chief VP | |
| Howard Robin, CEO and President and Director | |
| MD LAc, Chief Officer | |
| Brian MD, Chief Officer | |
| John Northcott, Strategic Advisor | |
| Loui Madakamutil, VP Research | |
| Robert Bacci, Senior Operations | |
| Jillian Thomsen, Chief Accounting Officer and Sr. VP of Fin. | |
Nektar Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nektar Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Pair Trading with Nektar Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Nektar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nektar Therapeutics will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Nektar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nektar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nektar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nektar Therapeutics to buy it.
The correlation of Nektar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nektar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nektar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Nektar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Additional Tools for Nektar Stock Analysis
When running Nektar Therapeutics' price analysis, check to
measure Nektar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nektar Therapeutics is operating at the current time. Most of Nektar Therapeutics' value examination focuses on studying past and present price action to
predict the probability of Nektar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nektar Therapeutics' price. Additionally, you may evaluate how the addition of Nektar Therapeutics to your portfolios can decrease your overall portfolio volatility.